New Approvals, Trial Data, and Campaign Introduced in the Q4 2025 Multiple Myeloma Market 

GlaxoSmithKline announced Blenrep’s US and UK approvals, along with the presentation of study results. The DTC “Comeback Kid” campaign also premiered in a brochure promoting the brand’s efficacy, safety, dosing, and mechanism of action.

New long-term data from two CARTITUDE trials, the presentation of data, Q3 2025 financial results, and an update to Carvykti’s boxed warning were discussed in materials from Johnson and Johnson and Legend Biotech.

Johnson and Johnson touted Darzalex Faspro’s FDA approval for smoldering multiple myeloma, new data supporting its efficacy in combination with Tecvayli, and its showcasing of trial results at a conference. Meanwhile, Genmab discussed its Q3 2025 sales of Darzalex.

Regeneron discussed Lynozyfic’s new response and safety data from the LINKER-MM4 study, which were exhibited at a conference. The brand’s approval, relevant codes, and Lynozyfic Surround program were also advertised.

Healthcare professionals were informed about treatment center location tool updates, introduced to a bispecifics guide website, and notified that Johnson and Johnson was presenting data at a conference. Talvey’s HCP “Make Your Move” and DTC “Different Light” campaigns were also featured, along with Tecvayli’s physician-directed “Power” theme.